I’m all about making a lasting impact by teaming up with servant leaders who are obsessed with tackling big challenges in scalable, enduring ways. With 20+ years of experience launching and leading tech-driven startups, my focus is now on life sciences, driving novel therapeutics with cutting-edge platform technologies. I’m also into HealthTech, AI, Decentralization (DeSci, DeFi, DeEd), and real estate. If you’re building or investing in these areas, let’s connect.Currently, I’m the CEO and Co-founder of a stealth-mode biotech, where we’re pioneering a first-in-class therapy targeting adipose tissue. I also serve as Chief Business Officer at Keliomics, where we’re redefining organ-scale biology with a platform that preserves the full composition, structure, and function of primary human tissues.Before this, I co-founded and served as VP of Corporate Development at 4M Therapeutics, a biotech leveraging living human brain cells to develop neuroprotective small molecules and peptides for treating neuropsychiatric and neurodegenerative disorders. During the “biotech winter,” I helped secure over $7M in seed capital, and my research shifted our lead program, guided development candidate selection, and laid the foundation for a new composition of matter IP strategy. Our lead program—a small molecule GSK3B inhibitor—is now on track to enter clinical trials for the treatment of bipolar disorder in late 2025.Before 4M, I co-founded Firecracker, an adaptive learning platform that became a go-to resource for U.S. medical students before being acquired by Wolters Kluwer. Prior to that, I founded Firefly Health, an online community that grew to 40,000+ members before being acquired by a Co-Founder of Facebook.Earlier in my career, I served as Executive Director at the Foundation for International Medical Relief of Children (FIMRC), leading global healthcare initiatives. My journey began as an Administrative Resident and Six Sigma Greenbelt at New York-Presbyterian Hospital. I hold a degree in Biology and Health Policy from Harvard, where I researched neonatal hypoxia. Beyond academics, I was Editor-in-Chief of the Harvard Health Policy Review, President of the Harvard Health Policy Society, and before college, I played professional soccer, crafted pottery, and was a sponsored skateboarder.